Posted by Michael Wonder on 20 Feb 2024
Sandoz receives Health Canada approval for Jubbonti, first and only denosumab biosimilar for treatment of osteoporosis
20 February 2024 - Biosimilar Jubbonti approved for all indications of Prolia reference medicine.
Sandoz Canada is pleased to announce that Health Canada has provided authorisation to market Jubbonti (denosumab subcutaneous injection, reference medicine: Prolia).
